文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

前列腺癌根治性放疗中的图像引导放疗:随机对照试验(RIC试验)的5年结果

Image guided radiotherapy in curative treatment for prostate cancer. 5-year results from a randomized controlled trial (RIC-trial).
PubMed 文献 · Radiother Oncol · 2024-04-24

2012至2015年纳入260例中高危前列腺癌患者,随机分为每周2-D门静脉成像(CTV至PTV外放15 mm,A组)或每日3-D锥形束CT(外放7 mm,B组),处方剂量均为78 Gy/39次,全部接受激素治疗。5年时216例可分析,两组肠道症状、泌尿症状及健康相关生活质量均无显著差异,无进展生存相似(HR 1.01;95%CI 0.57-1.97)。

要点

  • 5年时两组患者报告的肠道症状各项及量表均无显著差异。
  • 两组自我报告的泌尿症状及健康相关生活质量亦无差异,症状评分均低。
  • B组较A组无进展生存相似,HR 1.01(95%CI 0.57-1.97)。

核心结论

  • 结果支持每周2-D和每日3-D图像引导放疗均为前列腺癌安全有效的治疗,并强调需在长期随访临床试验中评估技术进步。

研究设计与样本

  • 2012至2015年开展的随机对照试验,纳入260例中危或高危前列腺癌男性。
  • 随机分为A组(每周2-D门静脉成像,CTV至PTV外放15 mm)或B组(每日3-D锥形束计算机断层扫描,外放7 mm)。
  • 处方剂量均为78 Gy/39次,全部患者接受激素治疗。
  • 主要终点为患者报告的肠道症状,次要终点为患者报告的泌尿症状、健康相关生活质量和无进展生存。

主要发现

  • 5年时216例可分析,超过90%完成患者报告结局测量。
  • 两组肠道症状各项及量表均无显著差异。
  • 两组自我报告泌尿症状及健康相关生活质量均无差异,两组症状评分均低。
  • B组较A组无进展生存相似(HR 1.01;95%CI 0.57-1.97)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Between 2012 and 2015 we conducted a randomized controlled trial in prostate cancer patients comparing weekly 2-D portal imaging versus daily 3-D verification. AIM: To evaluate the clinical outcomes of image guided radiotherapy by presenting rectal and urinary side effects, health related quality of life and progression free survival after 5-years follow up of a randomized controlled trial. METHODS: We randomized 260 men with intermediate or high-risk prostate cancer to weekly 2-D portal imaging with 15 mm margin from CTV to PTV (Arm A) or daily 3-D cone-beam computer tomography with 7 mm margins (Arm B). Prescribed doses were 78 Gy/39 fractions. All patients received hormonal therapy. Primary end point was patient reported bowel symptoms and secondary outcomes were patient reported urinary symptoms, health- related quality of life and progression free survival. RESULTS: Of the 216 patients available for analyses at 5 years more than 90 % completed patient reported outcome measures. There were no significant differences between study arms for any single items nor scales evaluating bowel symptoms. There were also no differences in self-reported urinary symptoms nor in health-related quality of life. Symptom scores were low in both study arms. Progression free survival was similar in Arm B as compared to arm A (Hazard ratio 1.01; 95 % CI 0.57 to 1.97). CONCLUSIONS: Our results support that both 2-D weekly and 3-D daily image guided radiotherapy are safe and efficient treatments for PC and emphasize the need to evaluate technological progress in clinical trials with long follow-up.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Lund JÅ, Lydersen S, Aksnessæther B, et al. Image guided radiotherapy in curative treatment for prostate cancer. 5-year results from a randomized controlled trial (RIC-trial). Radiother Oncol. 2024. PMID: 38670265. doi:10.1016/j.radonc.2024.110309

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。